OSU-53

• Description:

  OSU-53 is an orally active AMPK activator (EC50: 0.3 μM) and a direct mTOR inhibitor. OSU-53 induces autophagy and increases conversion of LC3 I to LC3 II. OSU-53 also modulates energy homeostasis by suppressing fatty acid biosynthesis and shifting the metabolism to oxidation by up-regulating the expression of PGC1α and NRF-1. OSU-53 has antitumor activity in various tumor models, such as breast cancer and thyroid cancer[1][2].

• UNSPSC:

  12352005

• Target:

  AMPK; Atg8/LC3; Autophagy; mTOR

• Type:

  Reference compound

• Related Pathways:

  Autophagy; Epigenetics; PI3K/Akt/mTOR

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/osu-53.html

• Smiles:

  O=S (C1=CC=C ([N+] ([O-]) =O) C (C (F) (F) F) =C1) (NC2=CC=C (/C=C (SC (N3CC4 (C) CCCCC4) =O) /C3=O) C=C2) =O

• Molecular Formula:

  C25H24F3N3O6S2

• Molecular Weight:

  583.60

• References & Citations:

  [1]Plews RL, et al. A novel dual AMPK activator/mTOR inhibitor inhibits thyroid cancer cell growth. J Clin Endocrinol Metab. 2015 May;100 (5) :E748-56. |[2]Lee KH, et al. Targeting energy metabolic and oncogenic signaling pathways in triple-negative breast cancer by a novel adenosine monophosphate-activated protein kinase (AMPK) activator. J Biol Chem. 2011 Nov 11;286 (45) :39247-58.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  1290069-19-0